Currently Viewing:
Newsroom
Currently Reading
History of Migraine Linked to Development of Tinnitus, Other Cochlear Disorders
July 21, 2018 – Jaime Rosenberg
Men With Advanced Cancers Respond Better Than Women to Immune Checkpoint Inhibitors
July 20, 2018 – Samantha DiGrande
Urgent Change in Approach to HIV Pandemic is Needed, Report Says
July 20, 2018 – Jaime Rosenberg
Brain Iron Levels Associated With Disability, Disease Progression in MS
July 20, 2018 – Samantha DiGrande
Solution Will Keep Most Clinical Guidelines Online, This Time for a Fee
July 20, 2018 – Allison Inserro
5 Vulnerable Populations in Healthcare
July 20, 2018 – Laura Joszt
Who Uses e-Cigarettes More: Current Smokers or Former Smokers?
July 20, 2018 – Allison Inserro
AJMC® in the Press, July 20, 2018
July 20, 2018 – AJMC Staff
Rate of Osteoporosis Drug Treatment to Prevent Recurrent Fractures Dropping
July 20, 2018 – Allison Inserro

Scientists Discover Gene That May Cause Melanoma to Metastasize

Samantha DiGrande
A new study published Monday by scientists at the University of Massachusetts Medical School (UMMS) in Boston reports findings on a gene that is responsible for creating a protein that may help melanoma to grow and metastasize.
A new study published Monday by scientists at the University of Massachusetts Medical School (UMMS) in Boston reports findings on a gene that is responsible for creating a protein that may help melanoma to grow and metastasize. The study appears in the Journal of Clinical Investigation.

Researchers found 374 genes that were altered in zebrafish melanomas as well as human melanomas. GDF6 is a part of a class of proteins that are active during embryo development, called “growth differentiation factors.” In looking at human melanoma cells, researchers found that 80% of patient tumors had elevated levels of GDF6, and the level of the protein in a tumor correlated to the aggressiveness of the cancer. By comparison, for people with lower levels of GDF6, melanoma was less likely to metastasize, according to the study.

“Melanoma is an aggressive cancer and the most deadly form of skin cancer,” Craig J. Ceol, PhD, an assistant professor of molecular medicine at UMMS, said in a statement. “Although new therapies have shown effectiveness against melanoma, a majority of patients either do not respond to these therapies or develop resistance. What is so exciting about this discovery, is that it opens up a completely new therapeutic target for investigation. None of the current therapies on the market target GDF6 or its pathway. For patients with very aggressive or treatment-resistant forms of cancer, this is very important; there is great therapeutic potential when you combine a drug targeting GDF6 with current therapeutics.”

Though melanoma is very aggressive, it accounts for only around 1% of all skin cancers. The National Cancer Institute (NCI) estimates that 87,110 new cases of melanoma were diagnosed in 2017.

Ceol and his colleagues are currently looking at a way to “switch off” the gene that could potentially be used in a clinical setting. “Because GDF6 is a type of protein that acts outside the cell, it makes it much easier to target therapeutically. We’re already exploring how to use monoclonal antibodies to inhibit GDF6,” Ceol said.

Reference

Venkatesan AM, Vyas R, Grammann AK, et al. Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma [published online, December 4, 2017]. J Clin Invest. 2017; doi:10.1172/JCI92513

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!